GILD vs. MRNA: Gilead Sciences vs. Moderna Stock Comparison
How do Gilead Sciences (GILD) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Gilead Sciences (GILD) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | GILD | MRNA |
|---|---|---|
| Name | Gilead Sciences Inc. | Moderna Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 207.00 billion USD | 101.48 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 22, 1992 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GILD | MRNA |
|---|---|---|
| Total Return (1Y) | 45.69% | 1,031.66% |
| Total Return (3Y, Annualized) | 35.30% | 58.68% |
| Total Return (5Y, Annualized) | 25.00% | 3.23% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GILD | MRNA |
|---|---|---|
| Volatility (1Y, Annualized) | 27.57% | 194.88% |
| Beta (5Y) | 0.36 | 1.08 |
| Max Drawdown (5Y) | -26.59% | -93.93% |
| Avg. Volume (3M) | 5.98M | 21.61M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GILD | MRNA |
|---|---|---|
| Sharpe Ratio (1Y) | 1.50 | 5.27 |
| Sortino Ratio (1Y) | 2.48 | 20.44 |
Profitability
ROE (TTM)
Both Gilead Sciences (GILD) at -22.45% and Moderna (MRNA) at -39.00% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-22.45%
- Max
- 109.18%
- Q3
- 6.23%
- GILD
- -22.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Gilead Sciences (GILD) at -12.46% and Moderna (MRNA) at -141.43% report negative net margin values, usually indicating net losses over the period.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.46%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- GILD
- -12.46%
- Min
- -17.05%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
Operating Margin (TTM)
Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Gilead Sciences (GILD) reports 42.43%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
42.43%
- Max
- 83.12%
- GILD
- 42.43%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
Profitability Metrics
| Metric | GILD | MRNA |
|---|---|---|
| ROE (TTM) | -22.45% | -39.00% |
| ROA (TTM) | 13.47% | -13.26% |
| Net Margin (TTM) | -12.46% | -141.43% |
| Operating Margin (TTM) | 42.43% | -557.93% |
| Gross Margin (TTM) | 79.95% | -66.02% |
Growth
Revenue Growth
Gilead Sciences (GILD) at 2.39% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Gilead Sciences (GILD) reports EPS growth of 1,684.21%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.
Growth Metrics
| Metric | GILD | MRNA |
|---|---|---|
| Revenue Growth (YoY) | 2.39% | -39.92% |
| Revenue Growth (3Y CAGR) | 2.57% | -53.30% |
| EPS Growth (YoY) | 1,684.21% | -- |
| EPS Growth (3Y CAGR) | 23.04% | -- |
Financial Strength
Current Ratio (MRQ)
Both Gilead Sciences (GILD) at 1.38 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GILD
- 1.38
- Min
- 0.10
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
Debt / Equity (MRQ)
Moderna (MRNA) at 0.19 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.02
- GILD
- 2.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GILD | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.38 | 2.30 |
| Debt / Equity (MRQ) | 2.02 | 0.19 |
| Net Debt / EBITDA | 1.25 | -- |
Dividends
Dividend Yield (TTM)
Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- GILD
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Moderna (MRNA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.46%
- GILD
- 43.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GILD | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 1.94% | 0.00% |
| Dividend Payout Ratio (TTM) | 43.46% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Gilead Sciences (GILD) nor Moderna (MRNA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- GILD
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
P/S Ratio (TTM)
Gilead Sciences (GILD) at 6.68 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- GILD
- 6.68
- Q1
- 3.01
- Min
- 0.01
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Moderna (MRNA) at 11.58 sits in the upper P/B ratio quartile, and Gilead Sciences (GILD) at 15.88 prices even higher, above its industry range.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.88
- GILD
- 15.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GILD | MRNA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 6.68 | 45.55 |
| P/B Ratio (MRQ) | 15.88 | 11.58 |
| Free Cash Flow Yield (TTM) | 5.16% | 0.29% |